New York represents one of the most sophisticated healthcare markets globally. With institutions like the New York-Presbyterian Hospital, Mount Sinai, and NYU Langone, the demand for Point-of-Care (POC) molecular diagnostics has reached an all-time high. Unlike traditional laboratory settings, the New York POC market requires systems that offer rapid turnaround times without sacrificing the analytical sensitivity of central lab PCR (Polymerase Chain Reaction) tests.
The city's unique industrial environment, including the growing biotech corridors in Long Island City and the Brooklyn Navy Yard, serves as a catalyst for integrating AI-driven diagnostic tools. We bridge the gap between high-volume manufacturing and local New York clinical requirements, ensuring that every molecular diagnostic unit meets the rigorous standards set by the New York State Department of Health (NYSDOH) Clinical Laboratory Evaluation Program (CLEP).
While local suppliers struggle with escalating logistics costs and labor shortages, our Shenzhen-based manufacturing hub provides a resilient supply chain that ensures New York hospitals and diagnostic centers have access to High-Flux Dialyzers and Chemiluminescence Immunoassay Systems with zero downtime. Our proximity to the global electronics heartland allows us to integrate the latest microfluidic and sensor technology into POC devices faster than domestic competitors.
Established in 2017, Shenzhen BioX Medical Co., Ltd. operates at the nexus of technology and manufacturing efficiency. With over 9,000 square meters of state-of-the-art facility space and 200+ specialized employees, we maintain a production capacity that can scale instantly to meet New York's seasonal demands (such as respiratory virus surges).
Our Global vs. Local Strategy: We combine the "Shenzhen Speed" of production with localized New York support. This means we offer:
The future of molecular diagnostics in New York is moving toward "Lab-on-a-Chip" and Multi-Omics integration. Our R&D focuses on several key technological pillars:
By 2027, BioX Medical aims to release a fully integrated "Home-to-Clinic" molecular hub, allowing chronic disease patients in New York to perform physician-monitored genetic biomarker tracking from their own residences.
Shenzhen BioX Medical Co., Ltd. is not just a factory; we are a multidisciplinary powerhouse. Our team of engineers and laboratory specialists ensures that every piece of IVD Diagnostic Equipment is subjected to rigorous quality control that exceeds ISO 13485 standards.
Our products are designed to meet international standards such as CE, ISO 13485, and we provide the necessary technical documentation to assist New York laboratories in obtaining NYSDOH CLEP validation. All medical power adapters are IEC/UL 60601-1 certified for clinical use.
We offer a hybrid support model: 24/7 digital technical assistance for AI software calibration and a network of local partners for hardware maintenance in the New York Tri-State area.
Due to our 9,000 sqm production capacity, we maintain stock of key components. Standard lead time for NY delivery is typically 2-4 weeks, including air freight and customs clearance.
Yes, BioX Medical offers comprehensive OEM and ODM services. We can customize molecular diagnostic analysis systems and pathogen detection solutions to fit your specific branding and clinical workflow requirements.
Partner with Shenzhen BioX Medical Co., Ltd. for the next generation of Point-of-Care Molecular Diagnostics.
Contact Our NY Sales Director
BioX Medical
